JP4714682B2 - 造血幹細胞及び該細胞による眼の血管新生性疾患の治療方法 - Google Patents

造血幹細胞及び該細胞による眼の血管新生性疾患の治療方法 Download PDF

Info

Publication number
JP4714682B2
JP4714682B2 JP2006513372A JP2006513372A JP4714682B2 JP 4714682 B2 JP4714682 B2 JP 4714682B2 JP 2006513372 A JP2006513372 A JP 2006513372A JP 2006513372 A JP2006513372 A JP 2006513372A JP 4714682 B2 JP4714682 B2 JP 4714682B2
Authority
JP
Japan
Prior art keywords
lin
hsc
cells
retinal
retina
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006513372A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006525806A (ja
Inventor
フリードランダー，マーテイン
篤史 大谷
ダシルバ，カレン
ハネカンプ，ステイシー
Original Assignee
ザ スクリプス リサーチ インスティチュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/628,783 external-priority patent/US7153501B2/en
Application filed by ザ スクリプス リサーチ インスティチュート filed Critical ザ スクリプス リサーチ インスティチュート
Publication of JP2006525806A publication Critical patent/JP2006525806A/ja
Application granted granted Critical
Publication of JP4714682B2 publication Critical patent/JP4714682B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2006513372A 2003-05-02 2004-04-28 造血幹細胞及び該細胞による眼の血管新生性疾患の治療方法 Expired - Fee Related JP4714682B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US46705103P 2003-05-02 2003-05-02
US60/467,051 2003-05-02
US10/628,783 US7153501B2 (en) 2002-07-25 2003-07-25 Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
US10/628,783 2003-07-25
PCT/US2004/012989 WO2004098499A2 (en) 2002-07-25 2004-04-28 Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2005373996A Division JP4714580B2 (ja) 2003-05-02 2005-12-27 造血幹細胞及び該細胞による眼の血管新生性疾患の治療方法

Publications (2)

Publication Number Publication Date
JP2006525806A JP2006525806A (ja) 2006-11-16
JP4714682B2 true JP4714682B2 (ja) 2011-06-29

Family

ID=36908146

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006513372A Expired - Fee Related JP4714682B2 (ja) 2003-05-02 2004-04-28 造血幹細胞及び該細胞による眼の血管新生性疾患の治療方法
JP2005373996A Expired - Fee Related JP4714580B2 (ja) 2003-05-02 2005-12-27 造血幹細胞及び該細胞による眼の血管新生性疾患の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2005373996A Expired - Fee Related JP4714580B2 (ja) 2003-05-02 2005-12-27 造血幹細胞及び該細胞による眼の血管新生性疾患の治療方法

Country Status (10)

Country Link
EP (2) EP1624758A4 (enExample)
JP (2) JP4714682B2 (enExample)
KR (3) KR101169261B1 (enExample)
CN (2) CN1831119B (enExample)
AU (2) AU2004237749B2 (enExample)
BR (1) BRPI0409861A (enExample)
CA (2) CA2524063C (enExample)
MX (2) MXPA05011750A (enExample)
RU (2) RU2345780C2 (enExample)
ZA (2) ZA200509752B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2554662A1 (en) * 2011-08-05 2013-02-06 M Maria Pia Cosma Methods of treatment of retinal degeneration diseases
CN110777124A (zh) 2011-10-27 2020-02-11 威尔斯达眼科制剂公司 编码视杆细胞来源的视锥细胞活力因子的载体
RU2495650C1 (ru) * 2012-02-29 2013-10-20 Федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения и социального развития Российской Федерации Трехкомпонентный комплекс для клеточной терапии в офтальмологии
RU2485922C1 (ru) * 2012-03-28 2013-06-27 Федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения и социального развития Российской Федерации Способ лечения "сухой" формы возрастной макулярной дегенерации
CN107043699B (zh) * 2017-04-25 2023-04-07 徐子雁 一种低能量激光诱导间充质干细胞血管化的试剂盒

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002033043A2 (en) * 2000-10-18 2002-04-25 Coriell Institute For Medical Research Method and marker for the isolation of human multipotent hematopoietic stem cells
CN1307300C (zh) * 2002-07-25 2007-03-28 斯克里普斯研究学院 造血干细胞和治疗新生血管性眼部疾病的方法

Also Published As

Publication number Publication date
EP1624758A2 (en) 2006-02-15
AU2005239702A1 (en) 2005-12-22
KR20060056420A (ko) 2006-05-24
JP2006166918A (ja) 2006-06-29
CN1816281A (zh) 2006-08-09
CA2524063A1 (en) 2004-11-18
CN100439493C (zh) 2008-12-03
EP1754783A1 (en) 2007-02-21
RU2389497C2 (ru) 2010-05-20
AU2005239702B2 (en) 2010-03-04
JP4714580B2 (ja) 2011-06-29
CA2524063C (en) 2015-02-17
CA2526670C (en) 2011-06-14
ZA200509756B (en) 2006-10-25
BRPI0409861A (pt) 2006-05-16
KR20120034251A (ko) 2012-04-10
ZA200509752B (en) 2006-11-29
KR101169261B1 (ko) 2012-08-03
MXPA05011752A (es) 2006-06-06
RU2005137569A (ru) 2006-06-10
CN1831119A (zh) 2006-09-13
CA2526670A1 (en) 2004-11-18
JP2006525806A (ja) 2006-11-16
EP1624758A4 (en) 2007-03-07
AU2004237749A1 (en) 2004-11-18
RU2006103574A (ru) 2007-08-20
KR101224375B1 (ko) 2013-01-21
RU2345780C2 (ru) 2009-02-10
MXPA05011750A (es) 2006-06-06
KR20060008968A (ko) 2006-01-27
AU2004237749B2 (en) 2011-09-15
CN1831119B (zh) 2010-05-26

Similar Documents

Publication Publication Date Title
US7838290B2 (en) Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
AU2003259687B2 (en) Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
JP2010509916A (ja) 単離された骨髄球様細胞集団及びそれを用いた治療方法
EP1935976B1 (en) Transfected myeloid-like cells for the treatment of retinopathy of prematurity and related diseases
US8900567B2 (en) Treatment of cone cell degeneration with transfected lineage negative hematopoietic stem cells
US20100303768A1 (en) Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
JP4714580B2 (ja) 造血幹細胞及び該細胞による眼の血管新生性疾患の治療方法
JP2008537478A (ja) 単離骨髄球様骨髄細胞集団及びそれを用いた治療方法
WO2006031467A9 (en) Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
AU2005285246B2 (en) Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
US20060104962A1 (en) Transfected hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090218

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100309

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100602

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100709

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101130

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110216

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110315

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110328

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees